AgelessRx wins $1M XPRIZE Healthspan Milestone 2 award for expanded clinical trial

AgelessRx/PEARL Trial

AgelessRx was named one of 10 Milestone 2 awardees in the XPRIZE Healthspan competition, receiving $1M to fund a fully powered human trial running 2026–2029. The trial will enroll approximately 186 adults aged 50–90, measuring effects on muscle, cognitive function, and immune status.

• $1M award supports trial through 2029 measuring muscle, cognitive, and immune function.
• ~186 participants, aged 50–90; decentralized design like PEARL, allowing remote enrollment.
• Trial designed to test AgelessRx's longevity-focused telemedicine model at scale.
• One of 20 finalists, 10 Milestone 2 awardees in the $101M XPRIZE Healthspan competition.